3aZEVvoRtp6McXy8TuIlR6lERn067Z

Investor Relations

NYSE: NVRO

Price

65.58 -0.11 ( -0.17% ) 4:02 4/18/19 Pricing delayed 20 minutes

Volume 823,571

Recent News

See All
March 19, 2019 Nevro Announces New CEO, Board Appointments and Agreement with Broadfin Capital
D. Keith Grossman Appointed as President and CEO
Two New Independent Directors, Bess Weatherman and Kevin O'Boyle, Appointed to the Board
Nevro Suspends Revenue Guidance While it Assesses Business Under New Leadership  Nevro Corp. (NYSE: NVRO) ("Nevro"), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that D. Keith Grossman has been appointed President and Chief Executive Officer of Nevro and a member of the Board of Directors (the "Board"), effective today. Mr. Grossman succeeds Rami Elghandour, who has stepped down as President, CEO and a director of the Company. Nevro also appointed two new independent directors, Elizabeth ("Bess") Weatherman and Kevin O'Boyle, effective immediately, and accepted the resignation of Ali Behbahani as a director. The leadership appointments follow constructive engagement with Broadfin Capital, LLC ("Broadfin"), a significant Nevro stockholder. "On...
February 21, 2019 Nevro Reports Fourth Quarter and Full Year 2018 Financial Results
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today reported financial results for the fourth quarter and full year ended December 31, 2018. 2018 Accomplishments and Recent Highlights Hired Michael Carter as Vice President, Global Sales to lead worldwide sales organization Launched Senza II: a smaller-footprint, advanced battery system with 10+ year life, and subsequently received FDA Approval for Conditional Full Body MRI Published a global registry of long-term real-world outcomes in 1,660 HF10 patients in Annals of Clinical and Translational Neurology. The long-term responder rates were 78%, nearly equivalent to those in SENZA-RCT. Furthermore, the overall explant rate in these patients was 3.7% all-cause, and 1.2% due to ineffective relief Presented positive clinical trial results at the 21st Annual Meeting of the North American Neuromodulation Society (NANS) which took place...
February 15, 2019 Nevro Files Lawsuit for Patent Infringement Against Stimwave in the U.S.
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that it has filed a lawsuit for patent infringement against Stimwave Technologies, Inc.  The lawsuit, filed in the United States District Court for the District of Delaware on February 14, 2019, asserts that Stimwave is infringing Nevro's patents covering inventions relating to Nevro's groundbreaking Senza® system and HF10® therapy.  The lawsuit seeks preliminary and permanent injunctive relief against further infringement as well as damages and attorney's fees. "Nevro was founded in 2006 to develop meaningful advances in the treatment of chronic pain to improve patients' lives," said Rami Elghandour, President and CEO of Nevro.  "Intellectual property is the basis for innovation in health sciences given the long development timelines, investment, and risk required to bring meaningful advances to market.  We are committed to...

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the SENZA® spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. The SENZA® system is the only SCS system that delivers Nevro's proprietary HF10™ therapy. Senza, Senza II, HF10, Nevro and the Nevro logo are trademarks of Nevro.

Senza, HF10, Nevro, and the Nevro logo are trademarks of Nevro Corp.